Newsroom
News from UCLB
SmartTarget Ltd announces sale of technology to Miami-based Intuitive Fusion LLC.
London, 24 January 2020 SmartTarget Ltd, a spinout company of UCL which successfully brought to market image fusion technology allowing accurate ...
UCLB launches applications for social challenge with London Borough of Camden
Are you developing an innovative piece of technology or research idea, at UCL, that has the potential to benefit society? ...
DiNAQOR AG Announces Research Collaboration and License Agreement with UCL to Investigate Gene Therapies for Heart Failure
DiNAQOR AG, a global gene therapy platform company, today announced a research collaboration and exclusive license agreement with UCL to ...
UCL developed FVIII gene therapy treatment shows excellent results
A FVIII gene therapy treatment, developed by world leading gene therapy expert, Professor Amit Nathwani at UCL has shown positive ...
Syncona makes a further $80 million commitment to Freeline
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, has announced Syncona Ltd (Syncona) has ...
Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent ...
Development of new treatment for severe hemophilia A on track
BioMarin today announced it has submitted a marketing application to the European Medicines Agency (EMA), for the investigational gene therapy, ...
UCLB launches funding for early-stage social ventures
UCLB, part of UCL Innovation & Enterprise, launches its search for early-stage social ventures to benefit from Proof of Concept ...
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO1 for Treatment of Acute Lymphoblastic Leukemia
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment ...
New commercialisation models to help bring more UCL discoveries to market
The launch of Portico Ventures sees the introduction of two new models for intellectual property (IP) commercialisation to support UCL ...
UCLB reaches an exclusive license agreement for the treatment of Alpha-1-Antitrypsin Deficiency
UCLB has concluded an exclusive agreement to license a collection of pre-clinical small molecule compounds for the treatment of alpha-1-antitrypsin ...
Echopoint raises £2.8m to address the ‘grey zone’ of heart disease treatment
Echopoint Medical Ltd, a spinout company from UCL, has raised £2.8m to develop optical sensing technology to help heart disease ...
UCLB spinout Endomag makes The Sunday Times Tech Track 100
Congratulations to medical device spinout Endomag who has been named in The Sunday Times Tech Track 100 list. The list ...
Four UCLB spinout companies are named finalists in the European Lifestars Awards
We are delighted to announce that four UCLB spinout companies have been named finalists for the 2019 European Lifestars Awards ...
Achillies Thereapeutics raises £100 million in oversubscribed series B financing
Achilles Therapeutics, a biopharmaceutical company launched in 2016, based on work led by Professor Charles Swanton of UCL and the ...
